Drugs / FNP-223
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06355531 | Jul 2024 → Nov 2026 expected | progressive supranuclear palsy | Ferrer Internacional S.A. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-06-17 | Ferrer Internacional S.A. | Regulatory We obtain FDA accelerated designation for FNP-223 in Progressive Supranuclear Palsy (PSP) ferrer.com ↗
We are pleased to announce that FNP-223, an innovative therapy licensed from Asceneuron and intended to slow the progression of progressive supranuclear palsy (PSP), has received the designation of an accelerated evaluation procedure or "fast-track" by the U.S. Food and Drug Administration (FDA). |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-17 | Ferrer Internacional S.A. | We obtain FDA accelerated designation for FNP-223 in Progressive Supranuclear Palsy (PSP) ferrer.com ↗ |
| 2023-02-22 | Asceneuron S.A. | Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP) asceneuron.com ↗ |
| 2022-04-01 | Asceneuron S.A. | Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models asceneuron.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FNP-223 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06355531 ↗ |
| Known as | ASN90 | “The OGA inhibitor ASN90/FNP-223 has the potential for disease modification in neurodegenerative diseases.” PMID 41239890 ↗ Nov 2025 |
| Action | Inhibit | “The OGA inhibitor ASN90/FNP-223 has the potential for disease modification in neurodegenerative diseases.” PMID 41239890 ↗ Nov 2025 |
| Route | Oral | “Participants will receive FNP-223 orally (PO), 3 times daily (TID).” NCT06355531 ↗ |
| Target | OGA | “The OGA inhibitor ASN90/FNP-223 has the potential for disease modification in neurodegenerative diseases.” PMID 41239890 ↗ Nov 2025 |